Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Spruce Biosciences, Inc. (SPRB : OTC)

• Company Description    Spruce Biosciences Inc. is a biopharmaceutical company. It focuses on developing and commercializing novel therapies for rare endocrine disorders. The company develops tildacerfont, an non-steroidal therapy which are in clinical stage. Spruce Biosciences Inc. is based in Daly City, California. Number of Employees: 21

• Price / Volume Information    Yesterday's Closing Price: $0.09 Daily Weekly Monthly 20 Day Moving Average: 268,417 shares Shares Outstanding: 42.23 (millions) Market Capitalization: $4.01 (millions) Beta: 2.40 52 Week High: $0.61 52 Week Low: $0.06 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 32.13% 25.49% 12 Week -32.09% -40.86% Year To Date -77.38% -78.87%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 611 GATEWAY BOULEVARD SUITE 740 - SOUTH SAN FRANCISCO,CA 94080 USA ph: 415-655-4168 fax: - investors@sprucebio.com http://www.sprucebiosciences.com

• General Corporate Information    Officers Javier Szwarcberg - Chief Executive Officer Michael Grey - Executive Chairman Samir Gharib - President and Chief Financial Officer Tiba Aynechi - Director Percival Barretto-Ko - Director Peer Information Spruce Biosciences, Inc. (CORR.) Spruce Biosciences, Inc. (RSPI) Spruce Biosciences, Inc. (CGXP) Spruce Biosciences, Inc. (BGEN) Spruce Biosciences, Inc. (GTBP) Spruce Biosciences, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 85209E109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/11/25 Share - Related Items Shares Outstanding: 42.23 Most Recent Split Date: (:1) Beta: 2.40 Market Capitalization: $4.01 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.22 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.85 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.26 Price/Cash Flow: - Price / Sales: 0.82 EPS Growth vs. Year Ago Period: -14.29% vs. Previous Quarter: 43.86% Sales Growth vs. Year Ago Period: -75.86% vs. Previous Quarter: 15.78% ROE 06/30/25 - - 03/31/25 - -143.15 12/31/24 - -102.86 ROA 06/30/25 - - 03/31/25 - -101.99 12/31/24 - -77.60 Current Ratio 06/30/25 - - 03/31/25 - 1.95 12/31/24 - 2.90 Quick Ratio 06/30/25 - - 03/31/25 - 1.95 12/31/24 - 2.90 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - -1,079.94 Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - -1,079.94 Pre-Tax Margin 06/30/25 - - 03/31/25 - -1,906.22 12/31/24 - -1,079.94 Book Value 06/30/25 - - 03/31/25 - 0.36 12/31/24 - 0.70 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.43

Powered by Zacks Investment Research ©